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Strengths and limitations of this study
 ► This study will be of high value to policies aimed 
at universal health coverage for HIV and tuberculo-
sis (TB) care in Ethiopia due to the financial risk of 
seeking care.
 ► Patient costs from this study can provide empiri-
cal bases for national HIV and TB programmes for 
adopting public finance or health insurance- based 
financing strategies.
 ► The patient costs for outpatient and inpatient HIV 
and TB care are presented together with income and 
consumption levels of households.
 ► The cost measurements relied on a patient’s ability 
to remember, which increases risk of recall bias.
 ► The HIV sampling consisted primarily of urban pop-
ulation and the TB study was limited to specific re-
gions of the country, therefore, these samples are 
not necessarily nationally representative.
AbStrACt
Objectives HIV and tuberculosis (TB) are major global 
health threats and can result in household financial 
hardships. Here, we aim to estimate the household 
economic burden and the incidence of catastrophic health 
expenditures (CHE) incurred by HIV and TB care across 
income quintiles in Ethiopia.
Design A cross- sectional survey.
Setting 27 health facilities in Afar and Oromia regions for 
TB, and nationwide household survey for HIV.
Participants A total of 1006 and 787 individuals seeking 
HIV and TB care were enrolled, respectively.
Outcome measures The economic burden (ie, direct 
and indirect cost) of HIV and TB care was estimated. In 
addition, the CHE incidence and intensity were determined 
using direct costs exceeding 10% of the household income 
threshold.
results The mean (SD) age of HIV and TB patient was 
40 (10), and 30 (14) years, respectively. The mean (SD) 
patient cost of HIV was $78 ($170) per year and $115 
($118) per TB episode. Out of the total cost, the direct cost 
of HIV and TB constituted 69% and 46%, respectively. 
The mean (SD) indirect cost was $24 ($66) per year for 
HIV and $63 ($83) per TB episode. The incidence of CHE 
for HIV was 20%; ranges from 43% in the poorest to 4% 
in the richest income quintile (p<0.001). Similarly, for TB, 
the CHE incidence was 40% and ranged between 58% 
and 20% among the poorest and richest income quintiles, 
respectively (p<0.001). This figure was higher for drug- 
resistant TB (62%).
Conclusions HIV and TB are causes of substantial 
economic burden and CHE, inequitably, affecting those in 
the poorest income quintile. Broadening the health policies 
to encompass interventions that reduce the high cost 
of HIV and TB care, particularly for the poor, is urgently 
needed.
bACkgrOunD
HIV and tuberculosis (TB) are major global 
health threats that cause a large finan-
cial burden on vulnerable populations. 
Global efforts, in the past two decades, have 
improved access to lifesaving HIV and TB 
interventions.1–3 More than 72 million lives 
have been saved between 2000 and 2018.4 5 
Nevertheless, high disease burden, inequality 
in utilisation of healthcare and service quality 
issues still exist.1–3 Better understanding of 
factors that affect use of these services would 
help countries to achieve universal health 
coverage (UHC) of HIV and TB services.
The population in need for care is still 
large. Globally, 1.7 million people acquired 
HIV infection and 10 million new TB cases 
occurred in 2018. In the same period, more 
than 2 million people died from HIV and 
TB.4 6 In Ethiopia, the prevalence of HIV 
among adults was 1% (CI: 0.7% to 1.4%) 
and the incidence rate of TB was 151/100 
000 in 2018.4 6 In order to end HIV and TB, 
a comprehensive approach should include 
medical and non- medical interventions such 
as socio- economic support and poverty alle-
viation.7 8
Although many countries, including Ethi-
opia, offer ‘free’ HIV and TB services, the 
implemented policies do not adequately 
provide realistic financial risk protection. The 
health budget in Ethiopia is low ($33.2 per 
capita) and 31% of overall health financing 
is out of pocket payments (OOP).9 10 Hence, 
patient and their families, often face both 
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direct and indirect costs, which create financial burden on 
households.11 12 A systematic review showed that individ-
uals in low- income countries spend a mean direct cost of 
$155 per drug susceptible TB and $406 per drug- resistant 
TB (DR- TB). The productivity losses were two to three 
times higher than the direct costs of drug susceptible and 
resistant cases, respectively.13 Similarly, for HIV, spending 
ranges from $95 to $2672 in sub- Saharan Africa.12 Such 
high costs are related to catastrophic health expendi-
ture (CHE), which occurs when the OOP exceeds 10% 
of annual income14 15 or 40% of household non- food 
expenditure.16 In addition, OOP expenses for HIV and 
TB care may crowd out consumption of basic needs 
and leave vulnerable households in debt/impoverish-
ment.12 17 18 Furthermore, high levels of patient cost may 
affect access to care, and lead to poor treatment outcome 
and prolonged period with infection.12 14 19–21
Many factors may lead to CHE; exemptions of HIV and 
TB services often applies to limited aspects of the basic 
care package (eg, CD4, viral load, acid- fast bacilli and 
GeneXpert tests), treatment (eg, antiretroviral therapy 
(ART), anti- TB drugs). Patients pay for prediagnostic 
services, ancillary medications, some laboratory testing, 
imaging, adverse event monitoring, hospitalisation, 
transportation, food, lodging, etc.19 22–24 In addition, 
unavailability of diagnostic services in public health facil-
ities pushes patients to seek care from expensive private 
providers.22 Furthermore, low health insurance coverage 
(around 24% as of 2019), and repeated follow- up visits 
were important contributing financial risk factors.25 26 It 
is also imperative that HIV and TB programmes, needs 
to monitor household protection from CHE (ie, financial 
risk protection) and its distribution across income groups 
(equity), as OOP health spending places greater burdens 
on the poor.27 28
In Ethiopia, few studies have been evaluating the extent 
of patient cost due to seeking HIV and TB care. The costs 
related to severe forms of the diseases and assessments 
across income or consumption groups were lacking from 
the studies reviewed.22 23 29 Furthermore, none studied 
predictors of CHE.22 23 29 Because HIV and TB are chronic 
diseases and intimately linked, it is reasonable to look at 
them jointly. This paper aims to estimate the economic 
burden and incidence of CHE incurred by standard HIV 
and TB care across income or consumption quintile 
among Ethiopian households. Moreover, we will assess 
factors associated with CHE for HIV and TB.
MethODS
Study setting and population
In this study, a nationwide household survey for HIV10 
and a cross- sectional health facility based survey for TB, 
were used to estimate direct and indirect costs, and CHE.
Data for HIV were collected from mid- September 2016 
to mid- October 2016. The total estimated number of 
people living with HIV (PLHIV) was 722747 in Ethiopia. 
However, for TB, data were collected from December 
2018 to September 2019 in three zones (ie, zone 3 of Afar 
region, and Jimma and Adama special zones of Oromia 
region). The three zones were purposely selected and 
represents 4 million people mirroring the country’s 
geographical and socio- economic heterogeneity. The 
zones account for 10% and 13% of the TB cases in 
Oromia and Afar regions (and 6% of the national preva-
lence), respectively.
Sample size and sampling technique
For HIV, PLHIV associations were used as a sampling 
frame to select HIV participants, as there is no national 
registry of PLHIV. The association operates in major cities 
in all regions and its members were primarily residents 
in urban areas. The estimated sample size was 4200. The 
response rate ranges from 92% to 100% across regions. 
A two- stage stratified cluster- sampling method was 
employed. In stage one, a sample of 105 HIV associations 
from a total of 588 were randomly selected and allocated 
to each region using probability proportional to the size. 
In stage two, 40 HIV members from each sampled asso-
ciation, in total 4171, were randomly selected and inter-
viewed. Among the study participants (ie, 4171), 1006 
had HIV- related care during the data collection period 
and were considered in our analysis.
For TB, the sample size was calculated using two- 
population proportion formula with 80% power, 5% type 
I error, 95% CI and using 39%21 of households incur CHE 
among the richest income quartile; and to detect 15% 
point difference revealed 186 samples for each quartile. 
The final sample size with 10% non- response rate was 818 
(of which 7% were DR- TB). Systematic random sampling 
was employed to select 27 public health facilities from the 
three zones. The total sample size was distributed propor-
tional to the TB case load.30
Patient and public involvement
The research question of this study is in line with the 
Ethiopian tuberculosis research plan developed through 
multiple consultative processes involving broader stake-
holders including patient representatives. We plan to 
disseminate the research findings through the national 
TB research conferences involving researchers, policy-
makers, stakeholders and affected communities.
Data collection tools and quality assurance
The data collection was based on a structured question-
naire adapted from the United States Agency for Inter-
national Development (USAID) for HIV and the World 
Health Organization (WHO) patient costing tool for 
TB.31 32 The questionnaire captures sociodemographic 
variables, direct cost, indirect cost, productivity loss, 
assets, income, consumptions and coping- related infor-
mation. We complemented clinical information for TB 
through review of medical records.The questionnaire was 
translated into local languages, pretested and modified 
accordingly. Trained data collectors under close super-
vision undertook the face- to- face interview. TB patients 
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with a minimum of 1 month on treatment were inter-
viewed consecutively and the expenses were reported 
retrospectively. This schedule of interview is based on 
WHO’s recommendation regarding the cost survey of TB 
patients.28 31 Whereas, for HIV, the expenditure in the 
past 4 weeks for outpatient and 6 months for inpatient 
care was gathered.
Patient cost
The costs of seeking standard HIV and TB care were 
estimated from a patient perspective. The expenditure 
related to routine care, HIV- related opportunistic infec-
tion and managing comorbidities was considered for HIV. 
Likewise, for TB episode, the expenditure in the pathway 
to care from onset of symptoms, diagnosis and comple-
tion of treatment was included.
Direct costs includes household expenditures for 
medical (ie, registration/consultation fees, laboratory 
tests, X- ray, medicines, hospital admission) and non- 
medical services (ie, special food/nutrition, transporta-
tion and guardian cost) net of reimbursement. Indirect 
costs constitute lost income following the disease episode. 
In order to estimate the indirect cost, patients were asked 
to estimate the time lost due to receiving and waiting for 
care, hospitalisation, transportation, lost working days 
and guardian time (TB). Then the total time lost was 
multiplied by an hourly wage rate, which was derived from 
monthly income/consumption by assuming 22 working 
days a month and 8 hours a day. For children less than 15 
years of age, non- medical direct and indirect TB cost was 
computed for the guardian. Total patient cost is the sum 
of all direct and indirect costs.
In order to annualise the cost, an average of four HIV 
outpatient visits and single TB episode outpatient visits 
was considered. The frequency of outpatient HIV visits 
per year was extrapolated on the basis of per capita 
healthcare visits an individual made over the last 1 month 
among all PLHIV interviewed. This proportion was annu-
alised to an approximately four visits per patient and year. 
The TB patient cost was extrapolated for the whole dura-
tion of TB episode based on an individual data reported 
retrospectively. All costs were gathered in local currency 
(Ethiopian Birr) and converted to US dollar ($) with the 
2019 exchange rate of $1=29.1468 Ethiopian Birr.33 For 
HIV, the cost was first converted to a reference period 
(2019) using Ethiopia’s consumer price index.34 Due to 
unavailability of data, we used household income (for 
HIV) and consumption aggregates (for TB) as a proxy 
for the household welfare measure and scaled to per 
adult equivalence (online supplementary appendix 1). 
In addition, participants were grouped into five- income/
consumption quintiles to reflect the socio- economic 
strata (online supplementary appendix 1).
An incidence of CHE occurs when direct costs (ie, OOP) 
exceed the 10% threshold of annual household income/
consumption.14 15 17 In addition to the 10% threshold, 
we carried out further analysis at 20% threshold of both 
OOP and total cost, and at 40% of non- food expenditure 
to allow for comparison.16 21 31 35 Furthermore, the distri-
bution of financial burden (measured as ratio of direct/
total costs to total household expenditure) across income 
quintiles was reported using headcount, overshoot 
and mean positive overshoot36 (online supplementary 
appendix 1).
Data analysis
Data was analysed using Stata V.16 software. The data was 
summarised using mean with SD or median with IQR due 
to skewed distribution. The cost was disaggregated by 
outpatient and inpatient care. A concentration index was 
used to assess health outcome measure inequality across 
income quintiles.36 37 Multivariate logistic regression was 
conducted to identify determinants of CHE by including 
significant variables in the univariate analysis. A stepwise 
regression approach was employed to develop the final 
model and an adjusted odds ratio (aOR) with 95% CI was 
reported. P value less than 0.05 declares statistical signif-
icance for each test. Multicollinearity was ruled out (vari-
ance inflation factor <5). Goodness of fit was checked by 
Hosmer- Lemeshow test.38
ethical consideration
Informed written consent was obtained from TB partic-
ipants. Oromia and Afar Regional Health Bureau, and 
respective zonal health offices provided permission to 
undertake the TB study.
reSultS
Out of the total 1006 HIV and 787 TB participants, 75% 
of HIV and 50% of TB were females (table 1). More than 
two- thirds of the study participants were in the age group 
between 25 to 44 years for HIV and 1 to 34 years for TB. 
The median family size was four (IQR, HIV: 3 to 5, IQR, 
TB: 3 to 6). The mean (SD) household annual income/
consumption per adult equivalence was $1188 ($1288) 
for HIV and $545 ($462) for TB. Seven per cent of TB 
patients were co- infected with HIV. Almost all (99%) of 
HIV and 91% of TB/HIV co- infected study participants 
were receiving ART. About 22% and 6% of HIV and TB 
patients had both outpatient and inpatient care, respec-
tively. The mean hospital stay was 11 days for HIV and 
10 days for TB. The mean (SD) time interval from first 
healthcare visit to TB diagnosis (health system delay) was 
14 (38) days and 85% of TB were diagnosed in public 
health facilities.
Patient cost of hIV and tb care
The total mean (SD) patient cost for HIV care was $78 
($170) per year and $115 ($118) for the entire duration 
of a TB episode (table 2). The mean (SD) direct cost was 
$54 ($144) for HIV and $53 ($59) for TB, which consti-
tutes 69% and 46% of the total cost, respectively. Medical 
costs contributed to 68% and 38% of the direct costs 
for HIV and TB, respectively. Diagnostics and medicine 
account for 39% of the total HIV cost. The mean (SD) 
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Table 1 Socio- demographic and clinical characteristics of 
HIV and TB study participants (Ethiopia)
Background 
characteristics
HIV (n=1006) TB (n=787)
N (%) N (%)
Gender
  Female 756 (75) 396 (50)
Age in years (mean, 
SD)
40 (10) 30 (14)
Age group
  <18 – 110 (14)
  18–24 14 (1) 190 (24)
  25–34 268 (27) 229 (29)
  35–44 435 (43) 117 (15)
  45–54 202 (20) 86 (11)
  55–64 58 (6) 32 (4)
  65+ 29 (3) 23 (3)
Marital status
  Single 38 (4) 309 (39)
  Married/living 
together
493 (49) 409 (52)
  Widowed 277 (27) 24 (3)
  Divorced 137 (14) 33 (4)
  Separated 61 (6) 11 (2)
Place of residence
  Urban 930 (92) 394 (50)
  Rural 76 (8) 393 (50)
Highest level of education
  Illiterate 290 (29) 257 (33)
  Elementary 457 (45) 334 (42)
  Secondary and 
higher
259 (26) 195 (25)
Family size
  ≤4 640 (64) 443 (56)
  >4 366 (36) 344 (44)
Annual household income/consumption
  Lowest 200 (20) 159 (20)
  Second 470 (21) 298 (20)
  Middle 797 (18) 443 (20)
  Fourth 1342 (20) 631 (20)
  Highest 3084 (21) 1198 (20)
ART status
  On ART 996 (99) 52 (91)
  Not on ART 10 (1) 5 (9)
Past history of illness*
  Yes 1006 (24) 61 (8)
  No 3165 (76) 726 (92)
Type of visit
  Outpatient 790 (79) 739 (94)
Continued
Background 
characteristics
HIV (n=1006) TB (n=787)
N (%) N (%)
  Inpatient 216 (22) 47 (6)
Number of visits per year/TB episode
  Outpatient 4428 (4 visits/
patient)
48 720 (70 visits/
patient)†
  Inpatient 249 (1 visit/
patient)
2409 (73 visits/
patient)†
Type of TB
  Pulmonary TB – 507 (65)
  Extra- pulmonary 
TB
– 222 (28)
  Drug- resistant TB – 57 (7)
*HIV- related comorbidities (HIV), and history of TB (TB).
†The number of total visits per patient reaches 125 for outpatient 
and 135 for inpatient drug- resistant TB cases.
ART, antiretroviral therapy; TB, tuberculosis.
Table 1 Continued
indirect cost was $24 ($66) for HIV per year, and $63 
($83) per TB episode. The productivity loss related to TB 
follow- up visits accounts for 36% of the total cost.
The mean (SD) total cost was $63 ($165) for annual 
outpatient HIV care visit and $110 ($114) for the whole 
duration of outpatient TB care (table 2). Similarly, the 
mean (SD) total cost for each hospitalisation was $96 
($139) for HIV and $105 ($78) for TB. For patients 
having both outpatient and inpatient visits, the mean cost 
reaches $133 ($178) (p<0.001) for HIV and $ 217 ($157) 
(p<0.001) for TB.
For TB, the patient costs incurred prior to initiation of 
treatment are equal to the cost from initiation to comple-
tion of TB treatment (paired t- test >0.05). The mean (SD) 
total cost for those with TB/HIV co- infection reached 
$188 ($33). Similarly, the total cost of care significantly 
varies by type of TB, it was $104 ($107) for pulmonary, 
$140 ($138) for extra- pulmonary and $446 ($732) for 
DR- TB (Kruskal- Wallis test 41.1, p<0.001) (online supple-
mentary appendix table A1).
Coping costs
HIV and TB care results in adverse financial consequences 
for households. Nearly 24% of HIV and 68% of TB study 
participants have adopted coping mechanisms. Nine 
per cent of HIV and 4% of TB patients have borrowed 
money; while, 2% of HIV and 19% of TB patients sold 
their household assets. Furthermore, 12% of HIV patients 
relied on family assistance and 16% of TB patients used 
their savings to cope with the costs. Only 2% of HIV and 
6% of TB participants are covered by health insurance.
As shown in figure 1, the spikes in the Pen’s parade 
graph revealed that the healthcare costs of HIV and TB 
cause a large decrease in annual income/consumption 
for many of the households. The consumption drop for 
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Table 2 Distribution of household direct, indirect and total cost of HIV and TB care across main cost category in Ethiopia 
(expressed in $)
Cost category ($)
HIV (n=1006) TB (n=729)
Outpatient
(per year)
Inpatient
(per single visit) Total
Outpatient
(per TB episode)
Inpatient
(per single visit) Total
(I) Direct medical cost
Consultation fee
  Mean (SD) 6 (15) 1 (5) 6 (15) 2 (5) 11 (16) 3 (7)
  Median (IQR) 0 (0–6) 0 (0–1) 0 (0–5) 1 (0–2) 7 (1–14) 1 (0–2)
Investigation cost
  Mean (SD) 14 (45) 9 (19) 15 (47) 8 (13) 14 (16) 9 (15)
  Median (IQR) 0 (0–11) 0 (0–9) 1 (0–12) 4 (0–12) 7 (3–18) 5 (0–13)
Drug cost*
  Mean (SD) 12 (40) 22 (63) 16 (48) 7 (14) 16 (21) 8 (16)
  Median (IQR) 0 (0–10) 4 (0–19) 1 (0–13) 1 (0–10) 8 (3–20) 2 (0–10)
Subtotal
  Mean (SD) 32 (88) 32 (77) 37 (98) 17 (24) 40 (37) 20 (30)
  Median (IQR) 4 (0–34) 8 (0–32) 6 (0–38) 10 (1–22) 30 (16–45) 11 (1–25)
(II) Direct non- medical cost
Transportation fee
  Mean (SD) 11 (55) 19 (34) 13 (53) 8 (10) 7 (7) 8 (10)
  Median (IQR) 2 (0–8) 6 (0–20) 3 (0–9) 5 (2–11) 7 (3–9) 5 (2–11)
Food/accommodation
  Mean (SD) 3 (50) 10 (30) 5 (48) 23 (29) 28 (34) 25 (31)
  Median (IQR) 0 0 (0–5) 0 15 (7–27) 16 (7–38) 16 (7–29)
Subtotal
  Mean (SD) 14 (80) 29 (49) 17 (76) 31 (34) 35 (36) 33 (37)
  Median (IQR) 2 (0–8) 10 (0–38) 3 (0–10) 21 (11–38) 20 (9–44) 21 (12–40)
Total direct cost
  Mean (SD) 46 (142) 60 (113) 54 (144) 48 (50) 75 (68) 53 (59)
  Median (IQR) 12 (1–45) 22 (4–74) 15 (2–57) 35 (17–61) 54 (26–94) 36 (18–64)
(III) Indirect cost
Foregone income before treatment†
  Mean (SD) 0 0 0 11 (28) 0 11 (26)
  Median (IQR) 0 0 0 0 (0–5) 0 0 (0–3)
Foregone income during treatment
  Mean (SD) 11 (44) 22 (41) 16 (50) 11 (26) 12 (31) 10 (26)
  Median (IQR) 0 8 (3–19) 0 (0–8) 0 (0–4) 0 0 (0–3)
Time loss related cost
  Mean (SD) 6 (19) 14 (52) 8 (30) 42 (59) 18 (24) 42 (58)
  Median (IQR) 2 (1–4) 2 (1–7) 2 (1–5) 27 (14–49) 8 (5–22) 27 (14–49)
Subtotal
  Mean (SD) 17 (54) 35 (75) 24 (66) 62 (84) 30 (37) 63 (83)
  Median (IQR) 3 (1–8) 13 (5–32) 4 (2–17) 36 (17–77) 9 (5–39) 36 (17–78)
(IV) Total cost
  Mean (SD) 63 (165) 96 (139) 78 (170) 110 (114) 105 (78) 115 (118)
  Median (IQR) 20 (5–63) 52 (25–109) 27 (7–80) 79 (46–140) 87(39-158) 81 (47–150)
*Drug other than anti- retroviral and anti- TB drugs.
†Not captured in HIV survey.
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Figure 1 Pen’s parade of household annual income/
consumption gross and net of payments for HIV (a) and TB 
care (b) (Ethiopia). TB,tuberculosis.
Table 3 Mean (median) HIV and TB patient costs per year across income quintiles in Ethiopia (expressed in $)
Disease category Income quintiles
Cost type
Direct Indirect Total cost
Mean
(SD)
Median 
(IQR)
Mean
(SD)
Median 
(IQR)
Mean
(SD)
Median
(IQR)
HIV Poorest 45 (92) 14 (2–48) 8 (15) 2 (1–7) 53 (97) 20 (3–61)
Poor 55 (170) 13 (0–52) 10 (19) 3 (1–9) 65 (173) 22 (4–65)
Middle 50 (118) 19 (3–49) 16 (30) 3 (2–16) 66 (136) 32 (7–65)
Rich 47 (89) 15 (3–57) 25 (51) 4 (3–20) 71 (111) 27 (7–81)
Richest 73 (206) 19 (3–79) 60 (124) 14 (5–59) 133 (262) 60 (12–132)
P value* 0.358 <0.001 <0.001
TB Poorest 31 (35) 23 (7–41) 19 (20) 11 (6–24) 50 (44) 36 (20–66)
Poor 44 (48) 27 (15–54) 36 (32) 27 (13–45) 79 (65) 60 (38–96)
Middle 49 (53) 36 (17–61) 57 (46) 40 (22–82) 106 (79) 82 (57–137)
Rich 61 (48) 49 (28–84) 79 (63) 58 (27–117) 140 (96) 118 (68–181)
Richest 78 (86) 54 (34–99) 124 (145) 70 (40–163) 202 (189) 148 (88–260)
P value* <0.001 <0.001 <0.001
*Kruskal- Wallis test.
TB, tuberculosis.
TB is more pronounced than the income drop for HIV 
(figure 1).
As shown in table 3, there are inequalities in OOP 
costs among HIV and TB participants. The total cost rises 
steadily across the income quintiles and is concentrated 
among the richer quintiles (ie, the richer the quintile, the 
higher the cost). From the lowest to the highest income/
consumption quintile, the mean (median) total cost of 
HIV increases from $53 ($20) to $133 ($60), with signif-
icant difference among income quintiles (Kruskal- Wallis 
test 44.7, p<0.001), and for TB the cost increases from $50 
($36) to $202 ($148) (Kruskal- Wallis test 206.5, p<0.001). 
In general, the median cost (both direct and indirect) 
seems to be a bit higher for TB patients as compared to 
that of HIV patients.
Incidence and intensity of Che
At the 10% threshold, the overall CHE incidence of HIV 
was 20% (197 households); with 43% of the poorest and 
4% of the richest household experiencing CHE (χ2 for 
trend −10.58, p<0.001). The incidence is 33% for individ-
uals with inpatient HIV care. The corresponding level of 
TB was 40% (291 households); with 58% and 20% of the 
poorest and richest income quintile experienced CHE, 
respectively (χ2 for trend −6.79, p<0.001) (table 4). The 
incidence was much higher for those with TB/HIV co- in-
fection (48%), DR- TB (62%) and was almost universal 
(94%) for hospitalised TB patients. At the 20% threshold 
of total expenses, 48% (353 households) of TB house-
holds experienced catastrophic total costs (figure 2)
(online supplementary appendix table A2).
In our study, for example, the mean overshoot of 
TB- related CHE was 6.3% (range: 1.9% to 15.3%). 
On average, households spent 6.3% beyond the 10% 
threshold for TB care. However, the average positive 
overshoot among households that experienced CHE 
was 15.8% (range: 9.2% to 26.6%). Thus, on average, 
households that experienced CHE spent 25.8% (10% 
threshold+mean positive overshoot) of their total annual 
consumption for TB care (figure 2)(online supplemen-
tary appendix table A2).
Inequality in financial risk
In addition, as shown in figure 3, inequality in finan-
cial risk across income/consumption groups exists. 
The concentration curves for HIV and TB care costs lie 
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Table 4 Multivariate logistic regression model of 
determinants of CHE for TB and HIV care at a 10% 
threshold of household income/consumption (Ethiopia)
Variable aOR (95% CI) P value
TB
Frequency of visits* 2.4 (1.9 to 3.1) <0.001
Hospitalisation
  No Ref.
  Yes 30.6 (4.8 to 199.8) 0.001
Income quintiles
  Richest Ref.
  Rich† 4.1 (2.1 to 7.8) <0.001
  Middle 4.9 (2.5 to 9.4) <0.001
  Poor 7.0 (3.6 to13.7) <0.001
  Poorest 14.6 (7.5 to 28.3) <0.001
Place of diagnosis
  Government Ref.
  Private 2.6 (1.5 to 4.3) <0.001
TB/HIV co- infection
  No Ref.
  Yes 3.2 (1.6 to 6.2) 0.001
Insurance (ie, CBHI)
  Yes Ref.
  No 2.7 (1.1 to 6.7) 0.038
Type of TB
  Bacteriologically- confirmed 
TB
Ref.
  Clinically- diagnosed TB 1.6 (1.0 to 2.8) 0.075
  Extra- pulmonary TB† 2.6 (1.8 to 4.0) <0.001
HIV
Frequency of visits per year* 1.07 (1.003 to 1.1) 0.04
Hospitalisation
  No Ref.
  Yes 3.3 (2.2 to 4.9) <0.001
Income quintiles
  Richest Ref.
  Rich 2.5 (1.1 to 5.8) 0.025
  Middle 4.5 (2.1 to 9.8) <0.001
  Poor 9.4 (4.5 to 19.5) <0.001
  Poorest 18.4 (8.9 to 37.7) <0.001
*Variable treated as continuous.
†Overall test is significant.
aOR, adjusted OR; CBHI, community- based health insurance; 
CHE, catastrophic health expenditures; TB, tuberculosis.
below the 45° line of equality, which shows a greater 
concentration of the costs among the rich. However, 
the financial burden is higher among the poor—the 
concentration curves for HIV and TB care expenditure 
in relation to income/consumption lie above the 45° 
line of equality.
Determinants of Che
In the multivariate analysis (table 4), three variables were 
independently associated with HIV related CHE: hospital-
ised patients (aOR: 3.3, 95% CI: 2.2 to 4.9), being poorest 
(aOR: 18.4, 95% CI: 8.9 to 37.7) and poor (aOR: 9.4, 95% 
CI: 4.5 to 19.5) were associated with catastrophic HIV 
care expenditures. Moreover, every additional visit for 
HIV care increases the odds of CHE by 7% (aOR: 1.07, 
95% CI: 1.003 to 1.1).
Seven variables were significantly associated with 
TB- related CHE (table 4): private facility diagnosis (aOR: 
2.6, 95% CI: 1.52 to 4.33), extra- pulmonary TB (aOR: 2.6, 
95% CI: 1.77 to 3.95), hospitalised patients (aOR: 30.6, 
95% CI: 4.77 to 199.83), being poorest (aOR: 14.6, 95% 
CI: 7.49 to 28.26) and TB/HIV co- infection (aOR: 3.2, 
95% CI: 1.63 to 6.15) were very likely to have TB- related 
CHE as compared with their counterparts after adjusting 
for other variables. Every additional visit for TB diag-
nosis increases the odds of experiencing CHE by 2.4 
times (aOR: 2.4, 95% CI: 1.92 to 3.05). Households with 
a health insurance scheme have protection from CHE 
(aOR 2.7; 95% CI 1.06 to 6.73).
DISCuSSIOn
In this study, we tried to estimate the OOP, total cost, 
incidence and determinants of CHE among individuals 
seeking HIV and TB care. This could provide valuable 
insight into the level of financial risk protection that a 
health system offers to its population.
hIV care costs and Che
In Ethiopia, where ART is given free- of- charge, PLHIV 
had to pay a total of $78 per year for HIV care ($19.5 per 
visit). The total HIV patient cost was equivalent to 7% of 
their annual income. As HIV requires lifelong care, such 
costs have a devastating impact on affected households. 
Our estimate was lower than the level and rate found in 
Cameroon 17%,39 Ethiopia 21%,23 Nepal 28.5%40 and 
South Africa (30%).41 These variations might arise from 
different study settings;39 40 high expenses of additional 
food and time loss.41 Similarly, more centralised HIV 
service delivery, delays in seeking care and long distance 
travel to access services may explain the difference with 
the previous study from Ethiopia. Additionally, the annual 
income in this study was twice that of the latter study.23 
However, a study on outpatient HIV care in Nigeria 
reported one- fourth of the cost in this study ($21.76).42
In our study, the average direct OOP expenditure for 
HIV care was $54 (ie, 69% of the total cost) and compa-
rable with that of the previous studies from Lao, Ethiopia 
and Nepal.19 23 40 Diagnostics, medicines and transpor-
tation costs constitute the largest share, and may pose a 
serious challenge to the success of the HIV programme. 
This calls for public financing policies (ie, free of charge 
diagnosis and treatment of HIV- related comorbidities 
for vulnerable groups) in the next steps of UHC expan-
sion. The productivity loss found here was one- half of 
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Figure 2 Interval plot (with 95% CI for the mean) of incidence and intensity of HIV and TB- related catastrophic health 
expenditures (CHE) across income quintiles, using 10% threshold (Ethiopia). CI, confidence interval, TB, tuberculosis.
that of the previous studies in Ethiopia and Nepal,23 40 
but one- fourth of that of Lao study.19 The difference in 
productivity losses with previous Ethiopian study could be 
attributed to a more centralised provision of HIV services 
and backlog of patients with advanced HIV diseases, 
unlike this study. The total costs of HIV care increases 
as income rises. The equity ratios (Q1:Q5, 0.39) showed 
higher expenditure among the richest income quintile, 
which is consistent with a study from southeast Nigeria.43
In our study, about a fifth (20%) of patients seeking 
HIV care experienced CHE. A study from India also 
depicts similar findings.44 However, the rate is lower than 
that of a study from Cameroon.39 Furthermore, the inci-
dence of HIV- related CHE remained relatively high; in 
particular, where poorest households suffer more. Similar 
socio- economic inequality was observed in previous 
studies,42 43 highlighting the importance of rendering 
equitable access to all in need of HIV care, particularly for 
the poor.39 Consistent with previous studies, being poor 
is associated with higher CHE.19 45 In addition, the poor 
were pushed further beyond the CHE threshold than the 
better off. This is of great concern, as health shocks are 
slightly managed by the poor through reduction of basic 
requirements to compensate for HIV care. Similar to 
previous studies, being hospitalised was a stronger deter-
minant of CHE.19 42
tb care costs and Che
In our study, patients with TB incurred a total cost of $115 
per episode and represents 21% of the annual household 
income, comparable to a study in South Africa (22%).46 
However, the total cost was less than the figure reported 
by previous studies in Ethiopia,22 29 but twice higher than 
the finding from southern Ethiopia.47 The variation in 
cost from previous studies arises from high expenditure 
on nutritional supplements ($72 vs $25),29 lower level of 
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Figure 3 Concentrations curves and index (I) for direct, 
indirect, total cost and share of OOP to income/consumption 
for (a) HIV and (b) TB services in Ethiopia. OOP,out- of- pocket 
payment; TB, tuberculosis.
seeking diagnostic care from public health facilities (64% 
vs 85%), high rates of clinically diagnosed cases (49% vs 
24%), diagnostic delays result in longer losses of working 
days,22 only direct cost captured.47 The average patient costs 
of DR- TB care were four times higher than drug- susceptible 
TB care. However, the DR- TB cost was three times lower 
than findings from another Ethiopian study.48 Still the 
devastating nature of DR- TB may put patients at special risk 
of CHE. The lower costs is mainly due to decentralisation 
of DR- TB services in recent years and the introduction of 
shorter multidrug- resistant TB treatment regimen (ie, 71% 
the study participants took 9- month to 12- month regimen).
In this study, one- half of the mean TB cost was incurred 
prior to initiation of treatment, which was consistent with 
many previous studies.11 21 22 49 50 This is mostly due to 
payment while demanding for proper diagnosis of TB.21 In 
addition to the financial burden of high pretreatment costs, 
it will be a barrier to complete the diagnostic process, and 
to timely access treatment and care. These emphasise the 
need for early case finding with rapid and point of care TB 
diagnostics, involvement of private care providers and insti-
tuting effective referral and linkage.47
The direct patient costs incurred constitute 46% of the 
total, comparable with findings from elsewhere (36%)51 
and systematic review results (40%).11 However, the propor-
tion was higher than the finding from southwestern Ethi-
opia (29%) and lower than the report from central Ethiopia 
(71%).22 29 Consistent with previous studies, non- medical 
and indirect costs represent a large share of the TB cost, 
while medical cost represent less than 20%.11 22 41 There-
fore, ensuring the expansion of TB service package through 
the effective integration of a health insurance scheme and 
decentralisation of services can reduce the direct costs.
A higher percentage of households incurs CHE for TB 
care (40%), which was comparable with studies from Fiji 
(40%), Ghana (47.6%), China (53%), Philippines (35%) 
and lower than reported rates from Ethiopia (63%), 
Nigeria (65%) and Benin (72%).29 49 50 52–54 However, CHE 
for TB care was higher in this study compared with findings 
in studies from India (21%) and Malaysia (6%).51 55 This 
variation might arise from cost estimation method, study 
setting, health system and socio- economic differences. The 
TB- related CHE was higher than the reported rate for HIV. 
The main reasons for this are the differences in treatment 
duration, follow- up frequency and care access between HIV 
and TB. TB patients experience a very onerous set of direct 
and indirect costs during diagnostic and intensive phase of 
directly observed short course therapy (ie, more intense 
for retreatment, extra- pulmonary and DR- TB cases). After 
treatment completion and possible sputum conversion, TB 
patients are less likely to face additional costs. Even though 
the annual cost of HIV care is lower, PLHIV faces these costs 
over its lifetime because HIV infection is a chronic disease 
that needs lifelong treatment. The comparison of incidence 
and intensity of CHE for TB and HIV is also complicated by 
the use of income for HIV and consumption for TB- related 
computations. In developing countries, income is a poor 
self- reported estimator of welfare due to more common 
informal employment, seasonal agricultural activities and 
widespread reluctance to disclose income.15 Therefore, 
income could understate the welfare of the household, 
whereas using consumption may overstate the condition of 
the household because of the use of dissaving/borrowing 
to smooth consumption over time.56
The mean overshoot for TB was 6.3% and the mean posi-
tive overshoot was 15.3%, both were similar with finding 
from Benin (7.8% and 14.8%) and Nigeria (6.0% and 
9.3%).50 52 TB, inequitably, imposes a greater burden of 
CHE on the poor households. Even though poor house-
holds tend to spend less, a higher share of their income is 
spent on seeking TB care.12 29 46 50 52 In addition, the excess 
CHE beyond the threshold was inequitably high among the 
poor. This finding is also in line with other studies.29 50 52 
Similar to other studies, hospitalisation, income status and 
TB/HIV coinfection were among the key determinants of 
TB- related CHE.28 49 50 52 55 In addition, even if the health 
insurance coverage (ie, community- based health insurance) 
was low and is limited to medical costs, we found protective 
effect of the scheme against CHE.57 However, health insur-
ance per se does not alleviate the major TB costs.
Study limitation and strengths
This study has some limitations. First, the cost measure-
ments relied on patient’s ability to remember, which 
increases risk of recall bias. However, we reduced the recall 
bias by interviewing participants who sought HIV and TB 
care within the past 1 month, when patients have a better 
recollection of their pathway to care.28 31 Second, HIV 
costs may be overestimated when aggregated over a 1- year 
period. Third, our findings may not be representative of 
all patients with TB in Ethiopia, as the study is limited to 
specific regions of the country. Similarly, the PLHIV associ-
ations operate in high HIV prevalence urban areas, where 
members of these associations may not be representative of 
both rural and non- members. Moreover, undetected HIV 
and TB cases not seeking care were not addressed. Despite 
 on M
arch 3, 2021 at U
niversity of B
ergen. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-036892 on 1 June 2020. D
ow
nloaded from
 
10 Assebe LF, et al. BMJ Open 2020;10:e036892. doi:10.1136/bmjopen-2020-036892
Open access 
these limitations, we used a standard tool and method to 
conduct the study. We believe that our study will be of high 
value to inform policy, at national and subnational levels, 
related to financial risk protection of both diseases, which is 
central in achieving UHC.
Policy implications
Despite OOP exemption of HIV and TB services in Ethi-
opia, we found that there is a large gap between the actual 
level of financial protection provided and the ideal goal. 
Our findings highlight important policy implications. 
First, more patient- centred care with effective diagnostics, 
appointment spacing for stable patients and community- 
based treatment are required to improve the delivery of 
HIV and TB services. Second, strategies are required to 
ensure social and financial risk protection for the house-
holds affected by HIV and TB. This requires effective 
integration of HIV and TB services with social and finan-
cial protection schemes, including the provision of travel 
vouchers, nutritional support and paid sick leaves through 
multisectoral collaboration.
COnCluSIOn
HIV and TB affected individuals and their households in 
Ethiopia face substantial costs in seeking care despite ‘free 
medical services’. The incidence of CHE related to HIV and 
TB care was high in all income quintiles, though more so 
in the poorest households. Policymakers should introduce 
patient- centred care; expand social and financial risk protec-
tion measures to minimise the high patient cost of HIV and 
TB care, particularly among vulnerable populations.
Acknowledgements The authors would like to thank all HIV and TB patients and 
supervisors who participated in this study. We thank all stakeholders; the Ministry 
of Health, Ethiopia; Ethiopian Public Health Institute; Oromia and Afar Regional 
Health Bureau with their respective districts for making this research possible.
Contributors LFA, KAJ, MTT: conception and design of the study. LFA: acquisition 
of data, data analysis and drafted the paper. LFA, AJ, KAJ, MTT, EN: critically 
reviewed the paper and gave approval for the final version to be published.
Funding Bill & Melinda Gates Foundation, grant number OPP1162384, supported 
this study.
Competing interests None declared.
Patient and public involvement Patients and/or the public were involved in the 
design, or conduct, or reporting or dissemination plans of this research. Refer to the 
Methods section for further details.
Patient consent for publication Not required.
ethics approval The study was approved by medical and health research 
ethics in Norway (2018/1647/REK) and Ethiopian Public Health Institute 
(EPHI- IRB-121–2018).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request. The data 
supporting the conclusion of this study can be available upon reasonable request 
from the corresponding author.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
OrCID iDs
Lelisa Fekadu Assebe http:// orcid. org/ 0000- 0002- 7857- 3349
Mieraf Taddesse Taddesse Tolla http:// orcid. org/ 0000- 0002- 9832- 7807
reFerenCeS
 1 Vitoria M, Granich R, Gilks CF, et al. The global fight against 
HIV/AIDS, tuberculosis, and malaria: current status and future 
perspectives. Am J Clin Pathol 2009;131:844–8.
 2 Danforth K, Granich R, Wiedeman D. Global mortality and morbidity 
of HIV/AIDS, 2017: 29–44.
 3 Bloom BR, Atun R, Cohen T. Tuberculosis, 2017: 233–313.
 4 World Health Organization. Global tuberculosis report 2019. Geneva: 
World Health Organization, 2019.
 5 World Health Organization. Who fact sheet on HIV/AIDS, 2019. 
Available: https://www. who. int/ news- room/ fact- sheets/ detail/ hiv- aids 
[Accessed 1 Sep 2019].
 6 UNAIDS. UNAIDS data, 2019. Available: https://www. unaids. org/ en/ 
resources/ documents/ 2019/ 2019- UNAIDS- data [Accessed 24 Nov 
2019].
 7 WHO. Implementing the end TB strategy: the essentials. Geneva: 
World Health Organization, 2015.
 8 Babigumira JB, Stergachis A, Veenstra DL, et al. Potential cost- 
effectiveness of universal access to modern contraceptives in 
Uganda. PLoS One 2012;7:e30735.
 9 The Federal Democratic Republic of Ethiopia Ministry of Health. 
Health Sector Transformation Plan 2015/16 - 2019/2020(2008-2012 
EFY. Addis Ababa, Ethiopia, 2015.
 10 Federal Democratic Republic of Ethiopia Ministry of Health. Ethiopia 
health accounts, 2016/17. Addis Ababa, Ethiopia, 2019.
 11 Tanimura T, Jaramillo E, Weil D, et al. Financial burden for 
tuberculosis patients in low- and middle- income countries: a 
systematic review. Eur Respir J 2014;43:1763–75.
 12 Russell S. The economic burden of illness for households in 
developing countries: a review of studies focusing on malaria, 
tuberculosis, and human immunodeficiency virus/acquired 
immunodeficiency syndrome. Am J Trop Med Hyg  
2004;71:147–55.
 13 Laurence YV, Griffiths UK, Vassall A. Costs to health services and 
the patient of treating tuberculosis: a systematic literature review. 
Pharmacoeconomics 2015;33:939–55.
 14 Wagstaff A, van Doorslaer E. Catastrophe and impoverishment in 
paying for health care: with applications to Vietnam 1993-1998. 
Health Econ 2003;12:921–33.
 15 O'Donnell O, Van Doorslaer E, Wagstaff A, et al. Analyzing health 
equity using household survey data a guide to techniques and their 
implementation, 2012.
 16 Xu K, Evans DB, Kawabata K, et al. Household catastrophic health 
expenditure: a multicountry analysis. Lancet 2003;362:111–7.
 17 Kawabata K, Xu K, Carrin G. Preventing impoverishment through 
protection against catastrophic health expenditure. Bull World Health 
Organ 2002;80:612.
 18 Lopera MM, Einarson TR, Iván Bula J. Out- Of- Pocket expenditures 
and coping strategies for people living with HIV: Bogotá, Colombia, 
2009. AIDS Care 2011;23:1602–8.
 19 Barennes H, Frichittavong A, Gripenberg M, et al. Evidence of 
high out of pocket spending for HIV care leading to catastrophic 
expenditure for affected patients in Lao people's Democratic 
Republic. PLoS One 2015;10:e0136664.
 20 Long Q, Smith H, Zhang T, et al. Patient medical costs for 
tuberculosis treatment and impact on adherence in China: a 
systematic review. BMC Public Health 2011;11:393.
 21 Wingfield T, Boccia D, Tovar M, et al. Defining catastrophic costs and 
comparing their importance for adverse tuberculosis outcome with 
multi- drug resistance: a prospective cohort study, Peru. PLoS Med 
2014;11:e1001675.
 22 Asres A, Jerene D, Deressa W. Pre- and post- diagnosis costs of 
tuberculosis to patients on directly observed treatment short course 
in districts of southwestern Ethiopia: a longitudinal study. J Health 
Popul Nutr 2018;37:15.
 23 Vassall A, Seme A, Compernolle P, et al. Patient costs of accessing 
collaborative tuberculosis and human immunodeficiency virus 
interventions in Ethiopia. Int J Tuberc Lung Dis  
2010;14:604–10.
 24 Mauch V, Bonsu F, Gyapong M, et al. Free tuberculosis diagnosis 
and treatment are not enough: patient cost evidence from three 
continents. Int J Tuberc Lung Dis 2013;17:381–7.
 25 Bhojani U, Thriveni B, Devadasan R, et al. Out- Of- Pocket healthcare 
payments on chronic conditions impoverish urban poor in Bangalore, 
India. BMC Public Health 2012;12:990.
 on M
arch 3, 2021 at U
niversity of B
ergen. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-036892 on 1 June 2020. D
ow
nloaded from
 
11Assebe LF, et al. BMJ Open 2020;10:e036892. doi:10.1136/bmjopen-2020-036892
Open access
 26 Ministry of Health, Ethiopia. Annual health sector performance report 
2011 EFY 2018/19. Addis Ababa, Ethiopia, 2011.
 27 World Health Organization. Health financing: monitoring sustainable 
development Goals—547 indicator 3.8.2; World Health organization: 
Geneva, Switzerland, 2019. Available: https://www. who. int/ health 
financing/topics/financial-protection/monitoring-sdg/en/. [Accessed 
5 Sep 2019].
 28 Ukwaja KN, Alobu I, Lgwenyi C, et al. The high cost of free 
tuberculosis services: patient and household costs associated 
with tuberculosis care in Ebonyi state, Nigeria. PLoS One 
2013;8:e73134.
 29 Getahun B, Wubie M, Dejenu G, et al. Tuberculosis care strategies 
and their economic consequences for patients: the missing link to 
end tuberculosis. Infect Dis Poverty 2016;5:93.
 30 Ministry of Health, Ethiopia. Health management information system 
(HMIS) annual TB and leprosy report. Addis Ababa, Ethiopia, 2016.
 31 WHO. WHO global TB programme. protocol for survey to determine 
direct and indirect costs due to TB and to estimate proportion of TB- 
affected households experiencing catastrophic costs, 2015.
 32 Federal Democratic Republic of Ethiopia Ministry of Health. Health 
service utilization and expenditure survey among people living with 
HIV (PLHIV), 2015/16. Addis Ababa, Ethiopia, 2017.
 33 National Bank of Ethiopia. Inter- bank daily foreign exchange rate in 
(USD)—archive, 2019. Available: https://www. nbe. gov. et/ market/ 
dailyexchange. html [Accessed 29 Oct 2019].
 34 International Monetary Fund. .World Economic Outlook Database, 
2015. Available: https://www. imf. org/ external/ pubs/ ft/ weo/ 2019/ 02/ 
weodata/ index. aspx [Accessed 17 May 2019].
 35 WHO Global TB Programme. Protocol for survey to determine direct 
and indirect costs due to TB and to estimate proportion of TB- 
affected households experiencing catastrophic costs, 2015.
 36 OvD O'Donnell, Wagstaff E, Adam Lindelow M. Analyzing health 
equity using household survey data, 2008.
 37 O'Donnell O, O'Neill S, Van Ourti T, et al. conindex: estimation of 
concentration indices. Stata J 2016;16:112–38.
 38 Gortmaker SL, Hosmer DW, Lemeshow S. Applied logistic 
regression. Contemp Sociol 1994;23:159.
 39 Boyer S, Abu- Zaineh M, Blanche J, et al. Does HIV services 
decentralization protect against the risk of catastrophic health 
expenditures?: some lessons from Cameroon. Health Serv Res 
2011;46:2029–56.
 40 Poudel AN, Newlands D, Simkhada P. The economic burden of HIV/
AIDS on individuals and households in Nepal: a quantitative study. 
BMC Health Serv Res 2017;17:76.
 41 Mudzengi D, Sweeney S, Hippner P, et al. The patient costs of care 
for those with TB and HIV: a cross- sectional study from South Africa. 
Health Policy Plan 2017;32:iv48–56.
 42 Etiaba E, Onwujekwe O, Torpey K, et al. What is the economic 
burden of Subsidized HIV/AIDS treatment services on patients in 
Nigeria and is this burden catastrophic to households? PLoS One 
2016;11:e0167117.
 43 Onwujekwe O, Dike N, Chukwuka C, et al. Examining catastrophic 
costs and benefit incidence of subsidized antiretroviral treatment (art) 
programme in south- east Nigeria. Health Policy 2009;90:223–9.
 44 Shukla M, Agarwal M, Singh J, et al. Catastrophic health expenditure 
amongst people living with HIV/AIDS availing antiretroviral treatment 
services at two tertiary care health facilities in district of northern 
India. Indian J Community Med 2015;6:323–8.
 45 Mnzava T, Mmari E, Berruti A. Drivers of patient costs in accessing 
HIV/AIDS services in Tanzania. J Int Assoc Provid AIDS Care 
2018;17:232595821877477.
 46 Foster N, Vassall A, Cleary S, et al. The economic burden 
of TB diagnosis and treatment in South Africa. Soc Sci Med 
2015;130:42–50.
 47 Datiko DG, Lindtjørn B, Cost LB. Cost and cost- effectiveness of 
treating smear- positive tuberculosis by health extension workers 
in Ethiopia: an ancillary cost- effectiveness analysis of community 
randomized trial. PLoS One 2010;5:e9158.
 48 Berhanu RH, Schnippel K, Kularatne R, et al. Can patients afford the 
cost of treatment for multidrug- resistant tuberculosis in Ethiopia? Int 
J Tuberc Lung Dis 2018;22:358–62.
 49 Duan W, Zhang W, Wu C, et al. Extent and determinants 
of catastrophic health expenditure for tuberculosis care in 
Chongqing municipality, China: a cross- sectional study. BMJ Open 
2019;9:e026638.
 50 Ukwaja KN, Alobu I, Abimbola S, et al. Household catastrophic 
payments for tuberculosis care in Nigeria: incidence, determinants, 
and policy implications for universal health coverage. Infect Dis 
Poverty 2013;2:21.
 51 Atif M, Sulaiman SAS, Shafie AA, et al. Resource utilization pattern 
and cost of tuberculosis treatment from the provider and patient 
perspectives in the state of Penang, Malaysia. BMC Health Serv Res 
2014;14:353.
 52 Laokri S, Dramaix- Wilmet M, Kassa F, et al. Assessing the economic 
burden of illness for tuberculosis patients in Benin: determinants and 
consequences of catastrophic health expenditures and inequities. 
Trop Med Int Health 2014;19:1249–58.
 53 Viney K, Islam T, Hoa NB, et al. The financial burden of tuberculosis 
for patients in the Western- Pacific region. Trop Med Infect Dis 
2019;4:tropicalmed4020094:94.
 54 Pedrazzoli D, Siroka A, Boccia D, et al. How affordable is TB care? 
findings from a nationwide TB patient cost survey in Ghana. Trop 
Med Int Health 2018;23:870–8.
 55 Prasanna T, Jeyashree K, Chinnakali P, et al. Catastrophic costs of 
tuberculosis care: a mixed methods study from Puducherry, India. 
Glob Health Action 2018;11:1477493.
 56 Tracking universal health coverage. 2017 global monitoring report. 
World Health Organization and International Bank for Reconstruction 
and Development / The World Bank, 2017.
 57 Zhou C, Long Q, Chen J, et al. The effect of NCMS on catastrophic 
health expenditure and impoverishment from tuberculosis care in 
China. Int J Equity Health 2016;15:172.
 on M
arch 3, 2021 at U
niversity of B
ergen. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-036892 on 1 June 2020. D
ow
nloaded from
 
